Short answer
Oncology Institute, Inc. (TOI) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $137M (up 36.7% year over year) with net income of −$17M.
Q3 2025 key financials · XBRL
- Revenue
- $137M
- +36.7% YoY · +14.0% QoQ
- Net income
- −$17M
- −2.4% YoY · +3.0% QoQ
- Operating margin
- -5.9%
- EPS (diluted)
- −$0.14
- +17.6% YoY · +0.0% QoQ
Source: XBRL data from the Oncology Institute, Inc. (TOI) Q3 2025 10-Q on SEC EDGAR. USD.
Oncology Institute, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $136.564M, up 36.7% YoY from $99.901M
- Dispensary strongest segment: $75.895M, up 57.4%; clinical trials weakest, down 75.6% to $474K
- Operating margin (6.0%) vs (13.9%) YoY; net loss margin (12.2%) vs (16.2%)
- Cash $27.658M; operating cash use $27.820M through nine months, improving $2.904M YoY
- Q3 ATM offering generated $11.8M gross proceeds; management expects sufficient liquidity for at least one year
Risk Factors
- New tax-law risk: OBBBA effective July 4, 2025, changing bonus depreciation and Section 163(j) interest-deduction calculations
- Regulatory exposure: OBBBA tax provisions affecting the Company and shareholders, with evaluation ongoing
- Financial risk: Section 163(j) changes may alter interest-deduction limits for taxable years beginning after December 31, 2024
- Near-term impact: Company expects OBBBA to have no material effect on financial statements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oncology Institute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.